Status:
COMPLETED
Acute Effect of Intensive Insulin Infusion on Intestinal Triglyceride-rich-lipoprotein-apoB48 Metabolism in Type 2 Diabetic Patients
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Type 2 Diabetes
Eligibility:
MALE
30-70 years
Phase:
NA
Brief Summary
Atherosclerotic cardiovascular disease (ASCD) is the first cause of morbidity and mortality at type 2 diabetes. The typical dyslipidemia that is associated with insulin resistance, which includes a po...
Detailed Description
Background: Atherosclerotic cardiovascular disease (ASCD) is the first cause of morbidity and mortality at type 2 diabetes. The typical dyslipidemia that is associated with insulin resistance, which i...
Eligibility Criteria
Inclusion
- type 2 diabetic patients according to the criteria of the American Diabetes Association
- body mass index between 25 and 40 kg/m2
- Subject the therapeutic care of which bases only on the oral anti-diabetics excepted of glitazones and inhibitors of alpha-glucosidases
- Subject without cardiovascular event in the previous 6 months or perturbing disease the lipid balance assessment (dysthyroidism, pituitary disease, adrenal disease)
- No anemia, no coagulation disturb, creatinine clearance \> 60 ml/min, fasting triglycerides \< 4g/l
Exclusion
- Hypersensitivity to egg
- Subject with severe disease associated with diabete
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00950209
Start Date
April 1 2008
End Date
July 1 2011
Last Update
February 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique-Hopitaux de Marseille
Marseille, France